| 01.10.22 | JPM Day 1: No M&A, but Pfizer, Bayer, Moderna, BioNTech pile on with milestone-heavy research collabs

Laden...

2 jaren geleden

Html
Tekst

Opportunities Beyond Hope: Immuno-Oncology Drug Development

Immuno-oncology drug development requires a thorough understanding of the immune system's role in cancer development and the unique challenges associated with evaluating therapeutic response. Download our white paper to explore the immune system's role in cancer development and the history and challenges of developing immunotherapies for cancer. Premier Research. Built for Biotech℠

Today's Rundown

JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more JPM 2022: Pfizer locks in 2 partners to solidify status as mRNA powerhouse BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts JPM 2022: Bayer taps CRISPR science from Doudna's lab in $1B biobucks Mammoth gene therapy deal Maze Therapeutics navigates $190M financing round as it plots course to the clinic Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, death JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal JPM 2022: Acadia to Stoke up pipeline with $60M central nervous system research pact JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more Fierce Healthcare's Fierce 15 of 2022 MeMed secures $93M to deliver tests for identifying viral, bacterial infections JPM, Day 1: Teladoc 2021 revenue to hit $2B, R1 RCM picks up Cloudmed in deal valued at $4.1B and more

Featured Story

JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more

By Ben Adams,Annalee Armstrong,Conor Hale,Kyle LaHucik

Join us for a rolling look at the top life sciences news coming out of this year's virtual J.P. Morgan healthcare conference.

Webinar: Improving the discovery of novel drugs with artificial intelligence

Thursday, February 3, 2022 | 2pm ET / 11am PT

This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now.

JPM 2022: Pfizer locks in 2 partners to solidify status as mRNA powerhouse

By Annalee Armstrong

Pfizer is determined to become an mRNA powerhouse, and it’s signing on two partners in that quest, including one that supplied tech that helped create the COVID-19 vaccine.

BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts

By Nick Paul Taylor

Sixteen months after a stinging FDA rejection, BioMarin Pharmaceutical looks to have the data it needs to win approval for its hemophilia A gene therapy in the U.S. The study found bleeding episodes remained very rare two years after the administration of valoctocogene roxaparvovec (ValRox).

JPM 2022: Bayer taps CRISPR science from Doudna's lab in $1B biobucks Mammoth gene therapy deal

By Angus Liu

Bayer is adding more building blocks to its cell and gene therapy ambition by tapping Mammoth Biosciences' CRISPR gene editing toolbox in a strategic collaboration with $40 million upfront and potentially worth over $1 billion.

Maze Therapeutics navigates $190M financing round as it plots course to the clinic

By Fraiser Kansteiner

Fierce 15 winner Maze Therapeutics just added $190 million to its fundraising pile in time to help its lead candidate, MZE001 for Pompe disease, make a clinical debut. Since its launch in 2019, the company ginned up approximately $400 million in investor cash.

Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, death

By Nick Paul Taylor

Novartis is coming for the COVID-19 antiviral market. After failing in hospitalized patients, Molecular Partners linked ensovibep to a 78% risk reduction in an earlier-stage population, prompting Novartis to pay 150 million Swiss francs ($163 million) for an asset that could soon add to the anti-omicron arsenal.

JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal

By Annalee Armstrong

Moderna is doling out a little bit of its COVID-19 vaccine cash in a $45 million oncology research deal with Carisma Therapeutics to develop up to a dozen targets.

JPM 2022: Acadia to Stoke up pipeline with $60M central nervous system research pact

By Annalee Armstrong

Acadia is looking to Stoke Therapeutics to breathe some air into its pipeline, with a $60 million upfront research pact to develop drugs for rare genetic diseases of the central nervous system. The upfront fee is accompanied by up to $907 million in milestones and also royalties down the line for Stoke.

JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more

By Eric Sagonowsky,Fraiser Kansteiner,Kevin Dunleavy,Angus Liu

Boot up those computers and get your J.P. Morgan healthcare conference meeting links ready, because it's set to be a week full of biopharma action.

Fierce Healthcare's Fierce 15 of 2022

By Paige Minemyer

Meet the winners of Fierce Healthcare's Fierce 15 of 2022.

MeMed secures $93M to deliver tests for identifying viral, bacterial infections

By Conor Hale

While most infectious disease tests search a sample for the presence of a particular pathogen, MeMed’s diagnostic collects evidence from the immune system itself and helps identify the culprit by gauging the body’s response to an invader.

JPM, Day 1: Teladoc 2021 revenue to hit $2B, R1 RCM picks up Cloudmed in deal valued at $4.1B and more

By Heather Landi,Paige Minemyer,Dave Muoio,Robert King,Rebecca Torrence,Anastassia Gliadkovskaya

Advocate Aurora gave an update on the non-profit hospital chain's efforts to pivot to a consumer-related healthcare company, including new acquisitions in technology providers.

White Paper: Eastern & Western Manufacturing Solutions for Late Life Cycle Products

Piramal Pharma Solutions is a CDMO that can support both early & late life cycle products, with Eastern and Western manufacturing solutions as your product needs evolve. Learn how our late life cycle tech transfer capabilities can support you.